Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · IEX Real-Time Price · USD
22.73
-0.31 (-1.35%)
Apr 19, 2024, 4:00 PM EDT - Market closed
Avidity Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Avidity Biosciences stock have an average target of 38, with a low estimate of 20 and a high estimate of 60. The average target predicts an increase of 67.18% from the current stock price of 22.73.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for RNA stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 6 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +53.98% | Apr 11, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $60 | Buy | Initiates | $60 | +163.97% | Mar 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $23 → $33 | Strong Buy | Maintains | $23 → $33 | +45.18% | Mar 5, 2024 |
| Needham | Needham | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +53.98% | Mar 4, 2024 |
| Needham | Needham | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +53.98% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
10.34M
from 9.56M
Increased by 8.18%
Revenue Next Year
7.07M
from 10.34M
Decreased by -31.64%
EPS This Year
-3.23
from -2.91
EPS Next Year
-3.57
from -3.23
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.3M | 15.8M | 254.1M | 719.9M | 1.5B |
| Avg | 10.3M | 7.1M | 85.9M | 438.3M | 1.3B |
| Low | n/a | n/a | 9.8M | 96.0M | 1.1B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 132.8% | 52.3% | 3,494.5% | 738.5% | 249.8% |
| Avg | 8.2% | -31.6% | 1,114.4% | 410.5% | 194.6% |
| Low | - | - | 38.6% | 11.9% | 145.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.85 | -2.90 | -1.73 | 2.05 | 10.86 |
| Avg | -3.23 | -3.57 | -3.22 | 1.37 | 7.51 |
| Low | -4.11 | -4.56 | -3.95 | 0.75 | 4.44 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 690.4% |
| Avg | - | - | - | - | 446.7% |
| Low | - | - | - | - | 223.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.